Musculoskeletal outcomes with Hereditary Haemochromatosis genetic variants: 11.5 year follow-up in a community cohort

Lucy R Banfield[1], Karen M Knapp[1], Luke C Pilling[2], David Melzer[2], Janice L Atkins[2]*

[1]The Department of Health and Care Professions, Faculty of Health and Life Sciences, University of Exeter, St Luke's Campus, Exeter, UK

[2]Epidemiology and Public Health Group, The Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, St Luke's Campus, Exeter, UK

Running Title: Hereditary haemochromatosis and musculoskeletal outcomes

***Corresponding author:** Epidemiology and Public Health Group, The Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, St Luke's Campus, Exeter, EX1 2LU, UK. Email: j.l.atkins@exeter.ac.uk

Abstract

Background: The iron overload disorder hereditary haemochromatosis (HH) is primarily caused by the homozygous *HFE* p.C282Y variant, but the scale of excess related musculoskeletal morbidity is uncertain.

Methods: We estimated HH-genotype associations with clinically diagnosed musculoskeletal outcomes and joint replacement surgeries in the UK Biobank community cohort. 451,143 European ancestry participants (40-70 years at baseline) were followed in hospital records (mean 11.5 years). Cox proportional hazards models estimated *HFE* p.C282Y and p.H63D associations with incident outcomes.

Results: Male p.C282Y homozygotes (n=1,294) had increased incidence of osteoarthritis (n=52, HR: 2.12 [95% CI:1.61-2.80]; $p=8.8*10^{-8)}$, hip replacement (n=88, HR:1.84 [95% CI: 1.49-2.27]; $p=1.6*10^{-8}$), knee replacement (n=61, HR:1.54 [95% CI:1.20-1.98]; $p=8.4*10^{-4}$), ankle and shoulder replacement, compared to males with no *HFE* mutations. Lifetable estimates demonstrated 30.4% of male homozygotes were projected to develop osteoarthritis and 15.5% to have hip replacements by age 75, versus 23.0% and 8.7% respectively without mutations. Male p.C282Y homozygotes also had increased incidence of femoral fractures (n=15, HR:1.72 [95% CI: 1.03-2.87]; p=0.04) and osteoporosis (n=21, HR:1.71 [95% CI: 1.11-2.64, p=0.02), although these association were limited to those with liver fibrosis/cirrhosis diagnoses. Female p.C282Y homozygotes had increased incidence of osteoarthritis only (n=57, HR:1.46, [95% CI: 1.12-1.89]; p=0.01). Male p.C282Y/p.H63D compound heterozygotes experienced a modest increased risk of hip replacements (n= 234, HR: 1.17 [95% CI: 1.02–1.33] p=0.02), but this did not pass multiple testing corrections.

Conclusions: In this large community cohort, the p.C282Y homozygote variant associated with substantial excess musculoskeletal morbidity in males. Wider iron overload or *HFE* genotype testing may be justified, including in orthopaedic clinics serving higher *HFE* variant prevalence populations.

Keywords: haemochromatosis; iron; joint replacement; musculoskeletal; osteoarthritis; osteoporosis; fractures.

Introduction

The iron overload disorder Hereditary Haemochromatosis (HH) is an autosomal recessive condition predominantly caused by mutations in the *HFE* gene, particularly the p.C282Y mutation, and to a lesser extent the p.H63D mutation. The p.C282Y mutation can cause accumulation of iron which builds up over time and is associated with osteoarthritis (OA), diabetes, liver disease, liver cancer as well as other conditions,[1–3] although only a minority of community populations with the p.C282Y homozygote variant actually develop associated clinical disease: i.e. the clinical penetrance is limited. The musculoskeletal impact of HH has been widely reported and it has long been recognised that patients with HH experience joint pain at a relatively young age.[4] In addition, the progression to joint replacement surgery in this population has also been reported. Previous analysis of UK Biobank data[2] (mean 7-year follow-up) found that in male p.C282Y homozygotes, the odds of hip replacement were raised (OR:2.62 [95% CI:1.97-3.49]; $P<0.001$). This is a similar incidence to a previous study which found a tripled risk of hip replacement in HH patients.[5]

Another widely reported musculoskeletal impact of HH is osteoporosis (OP), with evidence suggesting approximately 25% of patients with HH will suffer from OP,[6] and an even greater number from osteopaenia.[7] A sequela of OP is the risk of fracture and researchers have observed higher risks within HH patients. Early case studies presented unusual fractures in relatively young patients with markedly low bone mineral density (BMD) on dual-energy x-ray absorptiometry (DXA) scanning ranging from -3 to -5 SD's in the lumbar spine [8,9]. While increased odds of wrist fracture have been demonstrated in HH patients (OR:1.7, 95% CI:1.0-3.0, p=0.04),[10] the association of wider fragility fracture presentation has not been proven.[11]

Although excess musculoskeletal disease and associated surgical procedures clearly occur in clinically diagnosed HH patients, less is known about outcomes in community genotyped cohorts, especially to the older ages when joint replacements are common. Follow-up data over 11.5 years from the largest study of community dwelling participants who have been genotyped for *HFE* p.C282Y and p.H63D status, was used to examine associations between HH genotypes and musculoskeletal outcomes. The

current analysis of UK Biobank data advances our previous analyses [2] by including longer follow-up and a wider range of musculoskeletal outcomes.

Methods

UK Biobank participants

The UK Biobank study includes 502,464 volunteers aged 40 to 70 years. Baseline assessments (2006-10) included demographics, lifestyle, disease history, physiological measurements and collection of blood for genotyping[12]. Genotyping data were available for 451,143 participants of European ancestry with *HFE* p.C282Y (rs1800562) and *HFE* p.H63D (rs1799945) genotype information (see Supplementary Methods for details). Participants were followed-up via electronic hospital admissions data until 2020.

Baseline variables

Prevalent disease diagnoses were derived from self-reports at baseline though a verbal interview with a trained nurse, plus hospital inpatient data (National Health Service Hospital Episode Statistics) from 1996 to the baseline assessment, coded using International Classification of Diseases, 10th Revision (ICD-10). We examined a range of prevalent musculoskeletal outcomes, plus prevalent diagnoses of HH or liver cirrhosis/fibrosis. Height and weight were measured at baseline, and body mass index (BMI) was calculated in kg/m^2. Serum 25-hydroxyvitamin D (25[OH]D, a proxy for vitamin D) was measured in nanomoles per liter (nmol/L). Participants (n= 259,529) had bilateral calcaneal Quantitative Ultrasound Scanning (QUS) measurements obtained the Sahara Clinical Bone Sonometer (Hologic, Inc., Marlborough, MA, USA). Broadband ultrasound attenuation (BUA) and speed of sound (SOS) were derived, and combined to calculate the quantitative ultrasound index (QUI), any preventative maintenance, routine servicing and calibration of equipment within Biobank assessment centres is managed by the centre manager. [13]

Incident disease outcomes

Incident disease diagnoses, operations and procedures were identified during follow-up in hospital inpatient data, from baseline assessment to December 2020. Disease outcomes were coded using ICD-10. Operations and procedures were coded using the OPCS Classification of Interventions and Procedures version 4 (OPCS-4) (see Supplementary Table 1). Incident musculoskeletal outcomes examined included osteoarthritis (OA), hip/knee/shoulder or ankle replacement surgery, osteoporosis (OP), any reported fracture, femoral fracture (including neck of femur) and wrist fracture.

Statistical analysis

Cox proportional hazards regression tested associations between genotypes and risk of incident musculoskeletal diagnoses/surgical procedures. Results are presented in each of the p.C282Y-H63D genotype groups, compared to those without mutations. Incident outcomes excluded participants with each baseline prevalent diagnosis/surgical procedure (from self-reports at baseline, plus hospital inpatient data from 1996 to baseline). Models were stratified by sex and adjusted for age, assessment centre, genotyping array, and 10 genetic principal components generated in participants of European descent, accounting for population genetics substructure. Excess musculoskeletal outcomes are well documented in p.C282Y homozygotes. However, for other genotype groups we performed multiple testing correction (Bonferroni-corrected p-value of 0.006, dividing the 0.05 significance level by 9 musculoskeletal outcomes). Lifetable probabilities estimated hypothetical cumulative incident case numbers from age 40 to 75 years, in 5-year bands by genotype and sex. Proportional hazards assumptions for the musculoskeletal outcomes and replacement surgeries were tested with Schoenfeld residuals, which did not indicate violation of the assumption. Analyses were performed in Stata 15.1

Sensitivity analysis

Previous literature questioned the impact of liver disease on bone quality in HH patients[7,14] so a sensitivity analysis of the association between genotypes and OP was performed excluding participants

with a baseline liver fibrosis/cirrhosis diagnosis, to determine any relationship between liver disease and OP. We also excluded participants with a vitamin D deficiency (<25nmol/L).[15]

We also excluded participants who had a hip fracture code recorded within 5 days prior to the replacement surgery to determine rates of hip replacement surgery unrelated to trauma.

Primary care follow-up data were available in a subset of participants (n=209,795) from baseline until 2016-2017. Incident outcomes likely to be recorded in a primary care setting (OA and OP) were categorized from primary care 'Read codes' (see Supplementary Table 2).[16] In this subset of participants with primary care data, Cox proportional hazards regression were repeated to test association between genotypes and the risk of OA and OP (combining diagnoses in hospital inpatient records or primary care data).

To check whether results are biased due to inclusion of related participants we repeated the primary analyses randomly excluding one of each pair of participants related to the third degree or closer identified by KING kinship analysis[17] (381,000 participants remaining).

Results

Characteristics of participants

Analyses included 451,143 European descent participants aged 40 to 70 years at baseline, 54% of the sample were women and mean age was 56.8 years (SD 8.0). The mean follow-up period was 11.5 years (max 14.8). There were 2,890 p.C282Y homozygotes (0.6%), with 12.1% of male (156/1,294) and 3.4% of female (54/1,596) p.C282Y homozygotes diagnosed with haemochromatosis at baseline, increasing to 406 males (31.4%) and 302 females (18.9%) by the end of follow-up. Mean BMI was slightly lower in male p.C282Y homozygotes compared to those without mutations (27.6 vs 27.9 kg/m^2, p=0.02), but did not differ in females (26.9 vs 27 kg/m^2, p=0.21). Both male and female p.C282Y homozygotes had slightly lower mean vitamin D levels compared to those with no mutations (p=0.006

and p=0.01 respectively). There were no differences in BMD QUI scores in either male (p=0.07) or female (p=0.80) p.C282Y homozygotes compared to those without mutations. Male p.C282Y homozygotes had higher odds of baseline liver fibrosis/cirrhosis compared to those without mutations (1.7% vs 0.12%, OR:13.41, 95% CI:8.49-21.17, $p=8.5*10^{-29}$), but this was not observed in females (0.25% vs 0.11% OR:2.09, 95% CI:0.77-5.65, p=0.15) (Table 1).

Hazard ratios for incident musculoskeletal outcomes

During follow up, both male (n=52, HR: 2.12 [95% CI: 1.61-2.80] $p=8.8*10^{-8}$) and female (n=57 HR: 1.46 [95% CI: 1.12-1.89] p=0.01) p.C282Y homozygotes had increased risks of OA compared to those with neither variant. Our analysis found increased risks of joint replacement surgery in male p.C282Y homozygotes at the knee (n=61, HR: 1.54 [95% CI:1.2-1.98] $p=8.4*10^{-4}$), hip (n=88, HR: 1.84 [95% CI:1.49–2.27] $p=1.6*10^{-8}$), shoulder (n=2 HR: 7.55 [95% CI:1.79-31.86] p=0.006), and ankle (n=13, HR 20.08 [95% CI:10.96-36.78] $p=2.7*10^{-22}$) compared to those without mutations. However, increased risks of these four replacement surgeries were not seen in female p.C282Y homozygotes (Table 2).

There was a modest increased risk of hip and knee replacement within male p.C282Y heterozygotes (knee: n=841, HR: 1.08 [95% CI: 1.01-1.17] p=0.04, hip: n=1,083 HR: 1.09 [95% CI: 1.02–1.16] p=0.02). Male p.C282Y/p.H63D compound heterozygotes also demonstrated a modest increased risk of hip replacement (n= 234, HR: 1.17 [95% CI: 1.02–1.33] p=0.02) and male p.H63D heterozygotes had a modest increased risk of ankle replacement (n=37, HR: 1.59 [95% CI: 1.05-2.39) p=0.03). However, following Bonferroni correction for multiple testing, none of the above findings in p.C282Y heterozygous, p.H63D heterozygous or p.C282Y/p.H63D compound heterozygotes remained significant.

Analysis also demonstrated an increased risk of OP in male p.C282Y homozygotes (n=21, HR: 1.71 [95% CI: 1.11-2.64] p=0.02) and femoral fractures (n=15, HR: 1.72 [95% CI: 1.03-2.87] p=0.04). However, male p.C282Y homozygotes did not demonstrate increased risks of ‘any reported fractures’

or wrist fractures, although number of wrist fractures was low at n=3. The incidence of OP and fractures in female p.C282Y homozygotes when compared to those with mutations was not increased (Table 3).

Lifetable risks of incident musculoskeletal outcomes during follow-up

In lifetable estimates, 30.4% (95% CI: 26.4-34.9) of male p.C282Y homozygotes were projected to develop OA by age 75, compared to 23.0% (95% CI: 22.4-23.5) in those without mutations (excess proportion =7.5%). For hip replacement, 15.5% (95% CI: 12.6-19.1) of male p.C282Y homozygotes were projected to undergo hip replacement surgery, compared to 8.7% (95% CI: 8.5-9.0) of those without mutations (excess proportion =6.8%). In male p.C282Y homozygotes, by age 75 9.6% (95% CI: 7.4-12.4) were projected to undergo knee replacement surgery compared to 6.6% (95% CI: 6.3-6.8) in those without mutations (excess proportion of 3.0%).

Overall, the numbers for both shoulder and ankle replacement surgeries were low and only small excess proportions were identified; by age 75 male p.C282Y homozygotes were projected to have an excess of 1.8% of shoulder replacement and 0.3% excess of ankle replacements compared to those with no genetic variation. When comparing genotypes relative to risk of incidence rates for OP, the differences were relatively small; projected excess of 1.5% by age 75 and 1% excess in male P.C282Y homozygotes (see Tables 4, 5 and 6).

Sensitivity analyses

After excluding participants with a baseline diagnosis of fibrosis/cirrhosis (n=22), the association between male p.C282Y homozygosity and OP was attenuated (HR: 1.41 [95% CI:0.87-2.28] p=0.16] appearing to indicate the liver fibrosis does impact on bone health. The increased risk of OP in male p.C282Y homozygotes remained when those with a vitamin D level of <25nmol/L (n=329 p.C282Y homozygotes) were excluded from analysis. The increased risk of hip replacement in male p.C282Y homozygotes remained after excluding hip fracture codes recorded within 5 days prior to the

replacement surgery (n=16, HR: 1.84 [95% CI:1.48 – 2.2] $p=3.9*10^{-8}$), appearing to indicate that OA is the most common causative factor for the hip arthroplasty seen within these male homozygotes.

In the subset of participants with primary care data (n= 209,795), the association between male p.C282Y homozygosity and increased risk of OA (n=82, HR: 1.41 [95% CI:1.09-1.82] p=0.01) and OP (n=29, HR: 1.75 [95% CI:1.05-2.92] p=0.03) remained. However, the association between female p.C282Y homozygosity and increased risk of OA was attenuated (n=105, HR:1.04 [95% CI:0.83-1.32] p=0.72).

We repeated primary analysis of OA and OP after excluding one of each pair of participants related to the third degree or closer, to check whether results are biased as related participants share genetic and environmental factors, but also in the context of haemochromatosis are more likely to be referred by screening independent of clinical severity. Unrelated male p.C282Y homozygotes still had increased likelihood of diagnoses of OA and OP compared to unrelated participants with no *HFE* p.C282Y or p.H63D alleles.

Discussion

We used the UK Biobank cohort study (the largest community sample of HH-genotype individuals to date) to estimated HH-genotype associations with a range of musculoskeletal outcomes and joint replacement surgeries in 451,143 European ancestry participants. Over an 11.5 year follow-up period male p.C282Y homozygotes had increased risks of OA and joint replacement surgeries (hip, knee, shoulder and ankle), and increased risks of OP and femoral fracture (including neck of femur fracture) compared to those without mutations. There was a modest increase in risk of hip and knee replacement within male p.C282Y heterozygotes, and hip replacement within male p.C282Y/p.H63D compound heterozygotes. However, there were no consistent increases in risk in osteoarthritis in these genotype groups and results were no longer significant after correction for multiple testing. Therefore, more work is needed to replicate these findings.

The female p.C282Y homozygotes in our analysis only demonstrated an increased risk of OA compared to those with no genetic mutation. Our results provide the first estimates of cumulative risk to age 75 years; 30.4% of male p.C282Y homozygotes were projected to develop osteoarthritis and 15.5% to have hip replacements by age 75, versus 23.0% and 8.7% respectively without mutations.

The incidence of HH related arthropathy is well established, and there is continued debate as to whether the severity of iron overload is the main contributory factor, given the lack of evidence of any improvement in arthropathy symptoms, or slowing of disease progression following normalisation of iron levels.[18–20] We recently demonstrated that male p.C282Y homozygotes carrying other alleles that increase serum iron levels had modestly increased likelihood of OA diagnosis,[21] yet the effect is small and so the role of iron overload in OA onset remains to be fully elucidated. The male p.C282Y homozygotes in this community study demonstrated a twofold increased risk of developing OA, interestingly OA was the only musculoskeletal outcome analysed for this study that showed an increased risk in female p.C282Y homozygotes. Given that previous studies have demonstrated a potential under-reporting of OA diagnoses in primary care,[22] this relationship may be an underestimate. The increased likelihood of patients with HH requiring joint arthroplasty is another key area of research. It is thought that the excess iron in circulation may have a toxic effect on chondrocytes[23] and this progressive degeneration results in an increased need for joint arthroplasty in order to relieve symptoms and improve quality of life. The increased likelihood of this surgery has been demonstrated in previous studies [24] with a reported hazard ratio of 2.88 (95% CI:2.39–3.43) relative to primary hip arthroplasty, increasing when secondary hip replacements were assessed[5] echoing previous studies demonstrating an increased risk of homozygotes requiring bilateral total hip replacements (THR's)[25] in comparison to those with no p.C282Y mutation (OR: 5.86, 95% CI:2.36 – 14.57).[26]

Our analysis returned a hazard ratio of 1.84 (95% CI:1.49-2.27) for risk of hip replacement, reinforcing the evidence of greater risk for this type of surgery when compared to those without the genetic mutation. Our data also showed that within the 8,555 male hip replacements during the follow-up

period, 88 (1.0%) were in p.C282Y homozygotes. It did not however show increased risk for female p.C282Y homozygotes in contradiction to an earlier study identifying a greater risk to young female homozygotes,.[27] In apparent contradiction to our findings, a study by Oppl et al[28] was unable to establish a relationship between *HFE* genotype, OA and hip joint replacement surgery. However, as the mean age of their cohort was 59.4 years, and our survival analysis data did not show a larger excess burden relative to OA until 66 years and older, with a similar picture when related to hip replacements, this may explain the differing conclusions.

Increased HR were seen with respect to knee arthroplasty (HR: 1.54 95% CI:1.20-1.98) in male p.C282Y homozygotes, again in line with previously published studies.[10,27] Additionally, an increase in risk of ankle replacement surgery (HR: 20.08 [95% CI:10.96-36.78] $p=2.7*10^{-22}$) in male p.C282Y homozygotes was found. This risk estimate is much larger than that reported previously in a meta-analysis (RR: 8.94, [95% CI:3.85-20.78]), although that was based on HH diagnosis, not genotype as used in our current study.[29] It may be worth noting that ankle replacement surgery is still a relatively specialist operation performed in limited centres, ankle arthrodesis is a more likely procedure outside such centres, so our figures may underestimate true rate of surgical intervention.

Of additional relevance were increased risks relative to shoulder (HR: 7.55 [95% CI:1.79-31.86] p=0.006) seen within male p.C282Y homozygotes. The increased risks associated with shoulder replacement surgery have been reported in the literature, but primarily as case reports rather than larger scale cohort studies. A recent study determined that there was a trend towards shoulder arthroplasty [30] and although the number of shoulder replacement surgeries in the current study was small (n=2), this appears to be the first study to identify an increased risk of shoulder arthroplasty associated with HH-genotypes.

Evidence linking OP with HH has been accumulating over a number of years, however the cause of this relationship is still a subject of debate. Experimental studies have suggested that iron overload inhibits osteoblastic activity and hydroxyapatite growth leading to reduced bone formation. HH is linked with liver disease, diabetes and hypogonadism, which is a rare complication, these conditions are all associated with bone loss,[10] making a clear mechanism difficult to definitively establish. The two main factors that appear to impact on BMD relative to HH is either severity of iron overload and/or liver cirrhosis, with BMI, alkaline phosphatase (ALP) levels and genetic status also potentially influencing BMD. The published data is contradictory as to which of these is most strongly associated.[7,31] Other studies have demonstrated increased risk of OP independent of cirrhosis and hypogonadism but still related to severity of iron overload. In contrast, another more recent cross-sectional analysis found that whilst bone fragility was observed in a fifth of patients with HH, this was independent of the severity of iron overload and instead strongly associated with hepatic cirrhosis (OR 8.20 [95% CI 1.74-38.68], P= 0.008).[31]

In this cohort of male p.C282Y homozygotes there was an increased risk of incident OP (HR 1.71, [95% CI:1.11-2.64] p=0.02) and perhaps unsurprisingly also femoral fracture (HR 1.72, [95% CI:1.03-2.87] p=0.04). OP and OA have previously been identified as associated complications of HH but there has been less conclusive evidence around femoral fracture.

The other potential contributory factor suggested as a potential cause of the OP seen in this patient group is liver disease. In our cohort of male p.C282Y homozygotes, when we excluded those with a baseline diagnosis of liver fibrosis and cirrhosis the association of the genotype with OP was attenuated (HR: 1.41 [95% CI:0.87-2.28], p=0.16). This would appear to indicate that hepatocellular disease does contribute towards OP in the male p.C282Y homozygotes.

Given the increased risk of osteoporosis, we also reviewed the BMD data by sex and by genotype to ascertain whether there were any notable differences between homozygotes and controls. There was no

marked difference between homozygotes and other genotypes with the mean QUI remaining relatively comparable across all groups, albeit with the homozygotes appearing at the lower end of the range. These BMD results on the face of it appear to conflict with the increased risk of osteoporosis in the homozygotes and needs further investigation.

Although there were very slightly increased HR for females with respect to OP and fracture (any), these were not significant. These results add further evidence of the link between OP and HH, particularly in the male p.C282Y homozygotes. With regard fracture, this analysis again demonstrated an increased risk for the male p.C282Y homozygotes in respect of femoral fracture, including fracture of the femoral neck. There have been several studies which indicate a link between HH and fragility fracture,[8–10,31,32] however this still remains an under-researched aspect of HH. While the increased likelihood of fracture has previously been reported, there is variation in the degree of significance attached to this risk. The data presented in this paper provides evidence of increased risk, specifically of femoral fracture in this patient group, and given the morbidity and mortality associated with femoral fracture this is a clinically relevant finding. To date there does not appear to be any previously published data specifically related to femoral fracture and HH.

This study has several strengths in that it is the largest cohort of community genotyped p.C282Y homozygotes, being ten times larger than the next biggest study.[33] It has objective information on incident disease diagnoses and operations over a follow-up of 11.5 years. In terms of the validity of self-report as a means of accurate data gathering, this is addressed in the UK Biobank: Protocol for a large-scale prospective epidemiological resource[13 34] where self-report records were found to be more accurate than GP records; in addition, the validity of clinical coding, in particular ICD-10 codes has also been demonstrated via previous studies.[35,36]

However, there are some limitations to consider. UK Biobank participants were healthier than the general population at baseline,[37] but risk estimates are from incident disease/operations during follow-up so should be less susceptible to this bias at baseline. There is a small chance of misclassification bias

for self-reported disease outcomes at baseline, but this is minimised by the fact a trained nurse conducted the interviews with participants. No data were available on ferritin concentrations or transferrin saturation in UK Biobank, so we are unable to examine iron loading within genotype groups. However, there are many sources of error in ferritin levels, and genotyping is the gold standard especially for p.C282Y homozygotes for diagnosing hereditary haemochromatosis[38]. With widespread genotyping now becoming available, many patients can now be identified as being at risk of HH based on genotype, and this paper has quantified that risk. Also, Kieley et al has previously discussed the non-response of arthritis to de-ironing treatment[20]. We did not exclude those participants with a diagnosis of alcohol dependency, either via self-report or through hospital or primary care data, therefore the risk and incidence of fracture relative to excess alcohol intake needs further research. Also, we did not examine medication use such as corticosteroids or pain medication. Disease diagnosis may be an underestimate as primary care data were only available for a subset of the cohort. In addition, as the mean age of participants was 57 years, and this paper focussed on new incidence of OA the overall burden of HH related arthropathy, given its earlier onset, might also be underestimated. Lastly, we studied a European ancestry population so results may not be generalizable to more diverse populations.

Conclusions

Male p.C282Y homozygotes have an increased risk of OA, hip, knee, shoulder and ankle replacement, osteoporosis and femoral fracture compared to those without mutations. Female p.C282Y homozygotes had an increased risk of OA only. This may have implications for possible earlier diagnosis of HH by testing for iron overload and HFE genotypes of at risk individuals, including at orthopaedic and fracture clinics.

Ethics approval

The UK Biobank gained ethical approval from the North West Multi-Centre Research Ethics Committee (Research Ethics Committee reference 11/NW/0382). At the baseline assessment,

participants gave written informed consent for data collection, genotyping from blood samples, and linkage to electronic medical records for follow-up.

Author contributions

LRB, KMK, DM and JLA designed the study. LRB and JLA analysed the data and drafted the article. LRB, KMK, LCP, DM and JLA interpreted the data. KMK, DM and LCP revised the article critically for important intellectual content. All authors approved the final version to be published.

Data availability

Data are available on application to the UK Biobank (https://www.ukbiobank.ac.uk/enable-your-research/register).

Funding

This work was supported by an award to DM from the UK Medical Research Council (MR/S009892/1). JA is supported by an NIHR Advanced Fellowship (NIHR301844). DM, LP, KMK and LRB are supported by the University of Exeter.

Acknowledgements

This research was conducted using the UK Biobank resource, under application 14631. We thank the UK Biobank participants and coordinators for the dataset. We would also like to thank Professor Patrick Kiely (St Georges University Hospital NHS Trust) for his valuable and constructive suggestions during the writing of this paper. His willingness to give his time has been very much appreciated.

Conflict of interest

None declared.

References

1. Sood R, Bakashi R, Hegade VS, Kelly SM. Diagnosis and management of hereditary haemochromatosis. *Br J Gen Pract*. 2013;63(611):331-332. doi:10.3399/bjgp13X668410
2. Pilling LC, Tamosauskaite J, Jones G, et al. Common conditions associated with hereditary haemochromatosis genetic variants: Cohort study in UK Biobank. *BMJ*. 2019;364:k5222. doi:10.1136/bmj.k5222
3. Atkins JL, Pilling LC, Masoli JAH, et al. Association of Hemochromatosis HFE p.C282Y Homozygosity with Hepatic Malignancy. *JAMA - J Am Med Assoc*. 2020;324(20):2048-2057. doi:10.1001/jama.2020.21566
4. Richardson A, Prideaux A, Kiely P. Haemochromatosis: unexplained metacarpophalangeal or ankle arthropathy should prompt diagnostic tests: findings from two UK observational cohort studies. *Scand J Rheumatol*. 2017;461:69-74. doi:10.3109/03009742.2016.1155645doi.org/10.3109/03009742.2016.1155645
5. Elmberg M, Hultcrantz R, Simard JF, Carlsson Å, Askling J. Increased risk of arthropathies and joint replacement surgery in patients with genetic hemochromatosis: A study of 3,531 patients and their 11,794 first-degree relatives. *Arthritis Care Res*. 2013;65(5):678-685. doi:10.1002/acr.21883
6. Jandl NM, Rolvien T, Schmidt T, et al. Impaired Bone Microarchitecture in Patients with Hereditary Hemochromatosis and Skeletal Complications. *Calcif Tissue Int*. 2020;106(5):465-475. doi:10.1007/s00223-020-00658-7
7. Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S, Sinigaglia L. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. *Osteoporos Int*. 2009;20(4):549-555. doi:10.1007/s00198-008-0701-4
8. Duquenne M, Rohmer V, Legrand E, et al. Spontaneous multiple vertebral fractures revealed primary haemochromatosis. *Osteoporos Int*. 1996;6(4):338-340. doi:10.1007/BF01623396
9. Eyres KS, McCloskey E V., Fern ED, et al. Osteoporotic fractures: An unusual presentation of

haemochromatosis. *Bone*. 1992;13(6):431-433. doi:10.1016/8756-3282(92)90086-C

10. Richette P, Ottaviani S, Vicaut E, Bardin T. Musculoskeletal complications of hereditary hemochromatosis: A case-control study. *J Rheumatol*. 2010;37(10):2145-2150. doi:10.3899/jrheum.100234

11. Crooks CJ, West J, Solaymani-Dodaran M, Card TR. The epidemiology of haemochromatosis: A population-based study. *Aliment Pharmacol Ther*. 2009;29(2):183-192. doi:10.1111/j.1365-2036.2008.03874.x

12. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLoS Med*. 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779

13. Biobank UK. UK Biobank: Protocol for a Large-scale Prospective Epidemiological Resource. Published 2007. http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf

14. Sinigaglia L, Fargion S, Fracanzani AL, et al. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. *J Rheumatol*. 1997;24(9):1809-1813.

15. ROS vitamin D and bone health guideline | Independent professional body guideline | Guidelines.

16. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol*. 2015;44(3):827. doi:10.1093/IJE/DYV098

17. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship inference in genome-wide association studies. *Bioinformatics*. 2010;26(22):2867-2873. doi:10.1093/BIOINFORMATICS/BTQ559

18. Richardson A, Prideaux A, Kiely P. Haemochromatosis: unexplained metacarpophalangeal or ankle arthropathy should prompt diagnostic tests: findings from two UK observational cohort studies. *Scand J Rheumatol*. 2017;46(1):69-74. doi:10.3109/03009742.2016.1155645

19. Husar-Memmer E, Stadlmayr A, Datz C, Zwerina J. HFE-Related Hemochromatosis: An Update for the Rheumatologist. *Curr Rheumatol Rep*. 2014;16(393). doi:10.1007/s11926-013-0393-4

20. Kiely PDW. Haemochromatosis arthropathy – A conundrum of the celtic curse. *J R Coll Physicians Edinb*. 2018;48(3):233-238. doi:10.4997/JRCPE.2018.307

21. Pilling LC, Atkins JL, Melzer D. Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: associations in a large community cohort. *Hepatology*. Published online May 2022. doi:10.1002/HEP.32575

22. Yu D, Jordan KP, Peat G. Underrecording of osteoarthritis in United Kingdom primary care electronic health record data. *Clin Epidemiol*. 2018;10:1195-1201. doi:10.2147/CLEP.S160059

23. Lunn J V., Gallagher PM, Hegarty S, et al. The role of hereditary hemochromatosis in aseptic loosening following primary total hip arthroplasty. *J Orthop Res*. 2005;23(3):542-548. doi:10.1016/j.orthres.2004.11.004

24. Sahinbegovic E, Dallos T, Aigner E, et al. Hereditary Hemochromatosis as a Risk Factor for Joint Replacement Surgery. 2010;123(7):659-662.

25. Carroll GJ, Breidahl WH, Bulsara MK, Olynyk JK. Hereditary hemochromatosis is characterized by a clinically definable arthropathy that correlates with iron load. *Arthritis Rheum*. 2011;63(1):286-294. doi:10.1002/art.30094

26. Wang Y, Gurrin LC, Wluka AE, et al. HFE C282Y Homozygosity Is Associated with an Increased Risk of Total Hip Replacement for Osteoarthritis. *Semin Arthritis Rheum*. 2012;41(6):872-878. doi:10.1016/J.SEMARTHRIT.2011.11.003

27. Kröner PT, Mareth KF, Wijarnpreecha K, Palmer WC. Hereditary hemochromatosis is associated with increased use of joint replacement surgery: Results of a nationwide analysis. *Semin Arthritis Rheum*. Published online 2019. doi:10.1016/j.semarthrit.2019.10.003

28. Oppl B, Husar-Memmer E, Pfefferkorn S, et al. HFE hemochromatosis screening in patients with severe hip osteoarthritis: A prospective cross-sectional study. *PLoS One*. 2018;13(11). doi:10.1371/JOURNAL.PONE.0207415

29. Wijarnpreecha K, Aby ES, Panjawatanan P, et al. Hereditary hemochromatosis and risk of joint replacement surgery: A systematic review and meta-analysis. *Eur J Gastroenterol Hepatol*. Published online 2020:96-101. doi:10.1097/MEG.0000000000001704

30. Kröner PT, Mareth KF, Wijarnpreecha K, Palmer WC. Hereditary hemochromatosis is associated with increased use of joint replacement surgery: Results of a nationwide analysis. *Semin Arthritis Rheum*. 2020;50(2):360-365. doi:10.1016/j.semarthrit.2019.10.003

31. Nguyen CD, Morel V, Pierache A, et al. Bone and joint complications in patients with hereditary hemochromatosis: a cross-sectional study of 93 patients. *Ther Adv Musculoskelet Dis*. 2020;12. doi:10.1177/1759720X20939405

32. Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: Iron excess, gonadal deficiency, or others factors? *Ann Intern Med*. 1989;110(6):430-436. doi:10.7326/0003-4819-110-6-430

33. Adams PC, Barton JC, McLaren GD, et al. Screening for iron overload: Lessons from the HEmochromatosis and IRon Overload Screening (HEIRS) Study. *Can J Gastroenterol*. 2009;23(11):769. doi:10.1155/2009/839308

34. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet (London, England)*. 2002;360(9326):7-22. doi:10.1016/S0140-6736(02)09327-3

35. Quan H, Li B, Duncan Saunders L, et al. Assessing Validity of ICD-9-CM and ICD-10 Administrative Data in Recording Clinical Conditions in a Unique Dually Coded Database. *Health Serv Res*. 2008;43(4):1424. doi:10.1111/J.1475-6773.2007.00822.X

36. Peng M, Eastwood C, Boxill A, et al. Coding reliability and agreement of international classification of disease, 10th revision (ICD-10) codes in emergency department data. *Int J Popul Data Sci*. 2018;3(1):14. doi:10.23889/IJPDS.V3I1.445

37. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants with Those of the General Population. *Am J Epidemiol*. 2017;186(9):1026-1034. doi:10.1093/aje/kwx246

38. Adams PC. Epidemiology and diagnostic testing for hemochromatosis and iron overload. *Int J Lab Hematol*. 2015;37(S1):25-30. doi:10.1111/ijlh.12347

Table 1. Baseline characteristics of UK Biobank participants by p.C282Y/H63D genotypes and sex

Male						
	p.C282Y Homozygotes	**p.C282Y Heterozygotes**	**Compound Heterozygotes**	**H63D Homozygotes**	**H63D Heterozygotes**	**No mutations**
No (%)	1,294 (0.6)	24,575 (11.9)	4,954 (2.4)	4,674 (2.3)	47,988 (23.3)	122,845 (59.5)
No Diagnosed – HH (%)	156 (12.1)	27 (0.1)	29 (0.6)	8 (0.2)	17 (0.4)	30 (0.2)
Mean age, years (SD)	56.8 (8.2)	57.0 (8.1)	57.0 (8.1)	57.0 (8.1)	57.0 (8.1)	57.0 (8.1)
Mean QUI (SD)*	101.1 (23.5)	101.9(23.6)	102.3(22.3)	101.9(23.3)	102.5(23.3)	102.6(23.7)
Mean BMI, kg/m^2 (SD)	27.6 (4.1)	27.9 (4.2)	27.8 (4.2)	27.9 (4.2)	27.9 (4.3)	27.9 (4.2)
Mean Vit D, nmol/L (SD)	47.7 (19.6)	49.5 (21.2)	48.9 (21.2)	49.2 (21)	49.6 (21)	49.8 (21.1)
Fibrosis/Cirrhosis (%)	22 (1.7)	36 (0.2)	6 (0.1)	4 (0.1)	75 (0.2)	145 (0.1)

Female						
	p.C282y Homozygotes	**p.C282y Heterozygotes**	**Compound Heterozygotes**	**H63D Homozygotes**	**H63D Heterozygotes**	**No mutations**
No (%)	1,596 (0.7)	29,157 (11.9)	5,745 (2.3)	5,584 (2.3)	57,023 (23.3)	145,708 (59.5)
No Diagnosed – HH (%)	54 (3.4)	5 (0.02)	12 (0.2)	2 (0.04)	6 (0.01)	8 (0.01)
Mean age, years (SD)	56.9 (8.0)	56.5 (8.0)	56.5 (7.9)	56.6 (8.1)	56.6 (7.9)	56.6 (7.9)
Mean QUI (SD)*	93.4(19.5)	93.5(18.9)	94.0(18.6)	93.4(18.6)	93.9(19.0)	93.5(18.9)
Mean BMI, kg/m^2 (SD)	26.9 (5.1)	27 (5.1)	27.1 (5.2)	27.1 (5.3)	27 (5.1)	27 (5.2)
Mean Vitamin D, nmol/L (SD)	48.1 (20.3)	49.2 (21)	48.9 (20.7)	49.3 (20.6)	49.4 (21)	49.8 (20.9)
Fibrosis/Cirrhosis (%)	4 (0.3)	34 (0.1)	7 (0.1)	9 (0.2)	67 (0.1)	159 (0.1)

*Quantitative Ultrasound Index (QUI) data were available for a subset of n=259,529 participants.

QUI is a combined measurement including BUA and SOS, which provides an analogue of BMD.

Numbers presented are mean (SD) for continuous variables and N (%) for categorical variables.

BMD = bone mineral density; HH = hereditary haemochromatosis, SD = standard deviation

Table 2. Associations between p.C282Y/H63D genotypes and risk of osteoarthritis and joint replacements, by sex*

		Osteoarthritis		Knee Replacement		Hip Replacement		Shoulder Replacement		Ankle Replacement	
		HR (95% CI)	P Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value
No genetic mutations	**Male**	n=2,445 1.00		n=3,821 1.00		n=5,013 1.001		n=28 1.00		n=60 1.00	
	Female	n=3,568 1.00		n=4,925 1.00		n=7,946 1.00		n=95 1.00		n= 55 1.00	
p.C282y Homozygotes	**Male**	n= 52 2.12 (1.61-2.80)	$8.8*10^{-8}$	n=61 1.54 (1.20-1.98)	$8.4*10^{-4}$	n=88 1.84 (1.49-2.27)	$1.6*10^{-8}$	n=2 7.55 (1.79-31.86)	0.006	n=13 20.08 (10.96-36.78)	$2.7*10^{-22}$
	Female	n= 57 1.46 (1.12-1.89)	0.01	n=63 1.14 (0.89-1.46)	0.32	n=100 1.17 (0.96-1.42)	0.12	n=2 1.97 (0.49-8.04)	0.34	n=1 1.58 (0.22-11.42)	0.65
p.C282y Heterozygotes	**Male**	n=511 1.02 (0.92-1.12)	0.72	n=841 1.08 (1.01-1.17)	0.04	n=1,083 1.09 (1.02-1.16)	0.02	n=5 0.92 (0.35-2.37)	0.86	n=16 1.30 (0.75-2.26)	0.35
	Female	n= 753 1.05 (0.97-1.13)	0.24	n=1,001 1.02 (0.95-1.09)	0.55	n=1,535 0.98 (0.93-1.04)	0.49	n=15 0.82 (0.48-142)	0.49	n=6 0.53 (0.23-1.24)	0.14
Compound Heterozygotes	**Male**	n=96 0.96 (0.78-1.17)	0.67	n=145 0.92 (0.78-1.09)	0.34	n=234 1.17 (1.02-1.33)	0.02	n=0 N/A	N/A	n=1 0.41 (0.06-2.96)	0.38
	Female	n= 164 1.16 (0.99-1.36)	0.06	n=201 1.04 (0.91-1.20)	0.54	n=312 1.02 (0.91-1.14)	0.72	n=1 0.28 (0.04-2.03)	0.21	n=4 1.78 (0.65-4.93)	0.26
H63D Homozygotes	**Male**	n=81 0.87 (0.70-1.08)	0.21	n=134 0.92 (0.77-1.09)	0.33	n=192 1.01 (0.88-1.17)	0.85	n=1 0.95 (0.13-6.95)	0.96	n=2 0.88 (0.21-3.60)	0.86
	Female	n= 146 1.08 (0.91-1.27)	0.88	n=187 0.99 (0.86-1.15)	0.90	n=286 0.94 (0.83-1.06)	0.29	n=4 1.12 (0.41-3.04)	0.83	n=2 0.94 (0.23-3.87)	0.94
H63D Heterozygotes	**Male**	n=989 1.03 (0.96-1.11)	0.41	n=1,548 1.03 (0.97-1.10)	0.27	n=1,945 0.99 (0.94-1.05)	0.79	n=13 1.19 (0.62-2.30)	0.60	n=37 1.59 (1.05-2.39)	0.03
	Female	n=1,405 1.01 (0.95-1.07)	0.32	n=1,902 0.99 (0.94-1.04)	0.71	n=3,071 0.99 (0.95-1.04)	0.74	n=24 0.65 (0.42-1.02)	0.06	n=21 0.97 (0.59-1.61)	0.91

* HR (Hazard ratio) compared to those with neither HFE mutation. Cox proportional hazards regression models adjusted for age, assessment centre, genotyping array, and genetic principal components 1–10. Excluding prevalent disease diagnoses at baseline.

Table 3. Associations between p.C282Y/H63D genotypes and risk of osteoporosis and fractures, by sex*

		Osteoporosis		Femoral Fracture (inc. neck of femur)		Wrist Fracture		Any Reported fracture	
		HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
No genetic mutations	**Male**	n=1,181 1.00		n=824 1.00		n= 477 1.00		n=5,085 1.00	
	Female	n=5,357 1.00		n=1,663 1.00		n= 2,640 1.00		n=8,886 1.00	
p.C282y Homozygotes	**Male**	n=21 1.71 (1.11-2.64)	0.02	n= 15 1.72 (1.03-2.87)	0.04	n= 3 0.59 (0.19-1.83)	0.36	n= 66 1.24 (0.97-1.58)	0.09
	Female	n=71 1.16 (0.92-1.47)	0.21	n= 18 0.92 (0.58-1.46)	0.72	n= 32 1.05 (0.74-1.48)	0.79	n= 105 1.02 (0.85-1.24)	0.80
p.C282y Heterozygotes	**Male**	n=242 1.01 (0.88-1.60)	0.89	n= 179 1.07 (0.426)	0.43	n= 82 0.85 (0.68 – 1.08)	0.19	n= 1,013 0.98 (0.92-1.05)	0.62
	Female	n=1,034 0.97 (0.90-1.03)	0.30	n= 335 1.01 (0.90-1.13)	0.91	n= 552 1.03 (.94-1.13)	0.52	n= 1,814 1.01 (0.92-1.06)	0.64
Compound Heterozygotes	**Male**	n=51 1.05 (0.80-1.4)	0.69	n= 39 1.15 (0.83-1.59)	0.39	n= 19 0.98 (0.62-1.55)	0.93	n= 197 0.95 (0.82-1.10)	0.49
	Female	n=188 0.90 (0.78-1.04)	0.14	n= 72 1.11 (0.88-1.40)	0.39	n= 109 1.03 (0.85-1.25)	0.76	n= 350 0.99 (0.89-1.10)	0.82
H63D Homozygotes	**Male**	n=38 0.84 (.61-1.17)	0.32	n= 32 1.02 (0.72-1.45)	0.91	n= 8 0.44 (0.22-0.89)	0.02	n= 189 0.98 (0.84-1.13)	0.75
	Female	n=200 0.96 (0.84-1.11)	0.61	n= 54 0.83 (0.64-1.09)	0.19	n= 88 0.86 (0.70-1.07)	0.18	n= 311 0.91 (0.81-1.02)	0.10
H63D Heterozygotes	**Male**	n=457 0.99 (0.89-1.10)	0.84	n= 330 1.02 (0.90-1.16)	0.74	n= 167 0.90 (0.75-1.07)	0.23	n= 1,942 0.98 (0.93-1.03)	0.38
	Female	n=2,017 0.96 (0.92-1.01)	0.16	n= 658 1.02 (0.93-1.11)	0.71	n= 1,058 1.02 (0.95-1.10)	0.53	n= 3,529 1.02 (0.98-1.06)	0.45

HR (Hazard ratio) compared to those with neither HFE mutation. Cox proportional hazards regression models adjusted for age, assessment centre, genotyping array, and genetic principal components 1–10. Excluding prevalent operations/procedures at baseline.

Table 4. Lifetable estimates for incidence of musculoskeletal outcomes by sex and *HFE* genotypes (p.C282Y homozygotes vs no mutations)

	No Variants					C282Y homozygotes					
	Incident diagnosis					Incident diagnosis					
Outcome	**Cases**	**Survival function**	**%**	**(95% CI)**		**Cases**	**Survival function**	**%**	**(95% CI)**		**Difference, %**
Osteoarthritis											
Male age group, y											
40 - 45	71	0.9876	1.2	0.8	1.9	1	0.9910	0.9	0.1	6.2	**-0.3**
46 - 50	329	0.9705	3.0	2.5	3.5	3	0.9747	2.5	0.9	6.9	**-0.4**
51 - 55	714	0.9491	5.1	4.6	5.7	8	0.9522	4.8	2.6	8.8	**-0.3**
56 - 60	1258	0.9185	8.2	7.6	8.7	18	0.9081	9.2	6.3	13.3	**1.0**
61 - 65	2048	0.8801	12.0	11.5	12.6	30	0.8503	15.0	11.6	19.2	**3.0**
66 - 70	3079	0.8317	16.8	16.3	17.4	57	0.7613	23.9	20.1	28.2	**7.0**
71 - 75	3076	0.7705	23.0	22.4	23.5	35	0.6956	30.4	26.4	34.9	**7.5**
Female age group, y											
40 - 45	53	0.9924	0.8	0.5	1.1	0	1	*	*	*	*****
46 - 50	354	0.9774	2.3	1.9	2.6	3	0.9873	1.3	0.4	3.9	**-1.0**
51 - 55	1081	0.9514	4.9	4.5	5.3	16	0.9515	4.9	3.1	7.6	**0.1**
56 - 60	1794	0.9170	8.3	7.9	8.7	33	0.8929	10.7	8.2	13.9	**2.8**
61 - 65	2943	0.8726	12.7	12.3	13.2	42	0.8339	16.6	13.7	20.1	**4.6**
66 - 70	4147	0.8172	18.3	17.9	18.7	57	0.7650	23.5	20.3	27.1	**6.1**
71 - 75	4140	0.7437	25.6	25.2	26.1	38	0.7036	29.6	26.2	33.5	**4.7**
Osteoporosis											
Male age group, y											
40 - 45	2	0.9995	0.0	0.0	0.3	0	1	0.0	*	*	*****
46 - 50	13	0.9988	0.1	0.0	0.3	0	1	0.0	*	*	*****
51 - 55	35	0.9978	0.2	0.1	0.3	0	1	0.0	*	*	*****
56 - 60	75	0.9959	0.4	0.3	0.5	2	0.9952	0.5	0.1	1.9	**0.1**
61 - 65	152	0.9930	0.7	0.6	0.8	1	0.9934	0.7	0.2	2.1	**0.0**
66 - 70	251	0.9889	1.1	1.0	1.2	7	0.9824	1.8	0.9	3.3	**0.6**
71 - 75	354	0.9815	1.9	1.7	2.0	5	0.9718	2.8	1.7	4.7	**1.0**
Female age group, y											
40 - 45	9	0.9990	0.1	0.0	0.2	1	0.9913	0.9	0.1	6.0	**0.8**
46 - 50	28	0.9979	0.2	0.1	0.3	1	0.9877	1.2	0.3	5.4	**1.0**
51 - 55	130	0.9948	0.5	0.4	0.6	1	0.9857	1.4	0.4	5.2	**0.9**
56 - 60	347	0.9881	1.2	1.1	1.3	3	0.9803	2.0	0.7	5.3	**0.8**
61 - 65	725	0.9768	2.3	2.2	2.5	12	0.9628	3.7	2.1	6.6	**1.4**
66 - 70	1283	0.9587	4.1	4.0	4.3	20	0.9373	6.3	4.3	9.1	**2.1**
71 - 75	1646	0.9272	7.3	7.1	7.5	15	0.9125	8.8	6.5	11.8	**1.5**

The "Survival function" refers to the proportion of participants without a diagnosis in each age group for male and female p.C282Y homozygotes and those with no variants.
"Difference (%)" is the percentage difference in diagnoses by each age group in male and female p.C282Y homozygotes when compared to those with no variants.

Table 5. Lifetable estimates for incidence of hip and knee joint replacement surgery by sex and *HFE* genotypes (p.C282Y homozygotes vs no mutations)

	No Variants					C282Y homozygotes					
			Incident diagnosis					Incident diagnosis			
Outcome	**Cases**	**Survival function**	**%**	**(95% CI)**		**Cases**	**Survival function**	**%**	**(95% CI) %**		**Difference, %**
Hip Replacements											
Male age group, y											
40 - 45	5	0.9994	0.1	0.0	0.1	0	1.0000	0.0	*	*	*
46 - 50	70	0.9959	0.4	0.3	0.5	2	0.9908	0.9	0.2	3.6	**0.5**
51 - 55	210	0.9897	1.0	0.9	1.2	4	0.9804	2.0	0.9	4.5	**0.9**
56 - 60	378	0.9804	2.0	1.8	2.1	8	0.9611	3.9	2.3	6.6	**1.9**
61 - 65	771	0.9656	3.4	3.3	3.6	12	0.9397	6.0	4.1	8.9	**2.6**
66 - 70	1401	0.9429	5.7	5.5	5.9	28	0.8949	10.5	8.1	13.6	**4.8**
71 - 75	1465	0.9131	8.7	8.5	9.0	25	0.8448	15.5	12.6	19.1	**6.8**
Female age group, y											
40 - 45	10	0.9984	0.2	0.1	0.4	0	1.0000	*	*	*	*
46 - 50	69	0.9955	0.4	0.3	0.6	0	1.0000	*	*	*	*
51 - 55	279	0.9888	1.1	1.0	1.3	4	0.9918	0.8	0.3	2.2	**-0.3**
56 - 60	584	0.9776	2.2	2.1	2.4	8	0.9777	2.2	1.3	3.9	**0.0**
61 - 65	1219	0.9590	4.1	3.9	4.3	21	0.9475	5.3	3.8	7.3	**1.2**
66 - 70	2140	0.9298	7.0	6.8	7.3	25	0.9160	8.4	6.5	10.8	**1.4**
71 - 75	2352	0.8873	11.3	11.0	11.6	27	0.8735	12.7	10.3	15.5	**1.4**
Knee Replacement											
Male age group, y											
40 - 45	1	0.9999	0.0	0.0	0.1	0	1	*	*	*	*
46 - 50	6	0.9996	0.0	0.0	0.1	0	1	*	*	*	*
51 - 55	105	0.9965	0.3	0.3	0.4	2	0.9944	0.6	0.1	2.2	**0.2**
56 - 60	271	0.9899	1.0	0.9	1.1	7	0.9779	2.2	1.2	4.2	**1.2**
61 - 65	666	0.9771	2.3	2.2	2.4	14	0.9517	4.8	3.2	7.2	**2.5**
66 - 70	1119	0.9588	4.1	4.0	4.3	23	0.9158	8.4	6.4	11.1	**4.3**
71 - 75	1165	0.9344	6.6	6.3	6.8	6	0.9042	9.6	7.4	12.4	**3.0**
Female age group, y											
40 - 45	2	0.9998	0.0	0.0	0.1	0	1	*	*	*	*
46 - 50	25	0.9988	0.1	0.1	0.2	0	1	*	*	*	*
51 - 55	146	0.9954	0.5	0.4	0.5	4	0.9914	0.9	0.3	2.3	**0.4**
56 - 60	369	0.9883	1.2	1.1	1.3	4	0.9843	1.6	0.8	3.1	**0.4**
61 - 65	780	0.9764	2.4	2.2	2.5	9	0.9717	2.8	1.8	4.5	**0.5**
66 - 70	1406	0.9571	4.3	4.1	4.5	14	0.9543	4.6	3.2	6.5	**0.3**
71 - 75	1525	0.9293	7.1	6.9	7.3	24	0.9154	8.5	6.5	10.9	**1.4**

The "Survival function" refers to the proportion of participants without a diagnosis in each age group for male and female p.C282Y homozygotes and those with no variants.
"Difference (%)" is the percentage difference in diagnoses by each age group in male and female p.C282Y homozygotes when compared to those with no variants.

Table 6. Lifetable estimates for incidence of shoulder and ankle joint replacement surgery by sex and *HFE* genotypes (p.C282Y homozygotes vs no mutations)

	No Variants					**C282Y homozygotes**					
		Incident diagnosis					Incident diagnosis				
Outcome	**Cases**	**Survival function**	**%**	**(95% CI)**		**Cases**	**Survival function**	**%**	**(95% CI)**		**Difference, %**
Shoulder replacements											
Male age group, y											
40 - 45	0	1.0000	*	*	*	0	1.0000	*	*	*	*
46 - 50	2	0.9999	0.0	0.0	0.0	0	1.0000	*	*	*	*
51 - 55	0	0.9999	0.0	0.0	0.0	0	1.0000	*	*	*	*
56 - 60	2	0.9999	0.0	0.0	0.0	0	1.0000	*	*	*	*
61 - 65	5	0.9998	0.0	0.0	0.0	3	0.9943	0.6	0.2	1.8	**0.5**
66 - 70	3	0.9997	0.0	0.0	0.0	5	0.9866	1.3	0.7	2.7	**1.3**
71 - 75	9	0.9995	0.0	0.0	0.01	3	0.9813	1.9	1.0	3.4	**1.8**
Female age group, y											
40 - 45	0	1.0000	*	*	*	0	1.0000	*	*	*	*
46 - 50	1	1.0000	*	0.0	0.0	0	1.0000	*	*	*	*
51 - 55	1	0.9999	0.0	0.0	0.0	0	1.0000	*	*	*	*
56 - 60	3	0.9999	0.0	0.0	0.0	0	1.0000	*	*	*	*
61 - 65	12	0.9997	0.0	0.0	0.0	0	1.0000	*	*	*	*
66 - 70	18	0.9994	0.1	0.0	0.1	1	0.9988	0.1	0.0	0.9	**0.1**
71 - 75	33	0.9988	0.1	0.1	0.1	0	0.9988	0.1	0.0	0.9	**0.0**
Ankle replacements											
Male age group, y											
40 - 45	0	1.0000	*	*	*	0	1.0000	*	*	*	*
46 - 50	0	1.0000	*	*	*	0	1.0000	*	*	*	*
51 - 55	1	1.0000	0.0	0.0	0.0	0	1.0000	*	*	*	*
56 - 60	3	0.9999	0.0	0.0	0.0	1	0.9975	0.2	0.0	1.8	**0.2**
61 - 65	4	0.9998	0.0	0.0	0.0	1	0.9958	0.4	0.1	1.7	**0.4**
66 - 70	24	0.9994	0.1	0.0	0.1	0	0.9958	0.4	0.1	1.7	**0.4**
71 - 75	16	0.9991	0.1	0.1	0.1	0	0.9958	0.4	0.1	1.7	**0.3**
Female age group, y											
40 - 45	0	1.0000	*	*	*	0	1.0000	*	*	*	*
46 - 50	0	1.0000	*	*	*	0	1.0000	*	*	*	*
51 - 55	4	0.9999	0.0	0.0	0.0	0	1.0000	*	*	*	*
56 - 60	6	0.9998	0.0	0.0	0.0	0	1.0000	*	*	*	*
61 - 65	7	0.9997	0.0	0.0	0.0	0	1.0000	*	*	*	*
66 - 70	11	0.9995	0.0	0.0	0.1	1	0.9988	0.1	0.0	0.9	**0.1**
71 - 75	17	0.9992	0.1	0.1	0.1	1	0.9972	0.3	0.1	1.1	**0.2**

The "Survival function" refers to the proportion of participants without a diagnosis in each age group for male and female p.C282Y homozygotes and those with no variants.
"Difference (%)" is the percentage difference in diagnoses by each age group in male and female p.C282Y homozygotes when compared to those with no variants